rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses

Ítems similars

• rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
  per: Bart P, et al.
  Publicat: (2012-09-01)
• Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence
  per: Rujittika Mungmunpuntipantip, et al.
  Publicat: (2022-06-01)
• Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: case report
  per: Farah Naghashzadeh, et al.
  Publicat: (2022-04-01)
• Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
  per: Michelle C Crank, et al.
  Publicat: (2016-01-01)
• Clinical Trials of DNA and Recombinant Adenovector (rAd) Vaccines for HIV
  per: Graham Barney S
  Publicat: (2005-12-01)